Texas Liver Institute
Texas Liver Institute
San Antonio, Texas, United States5 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome | Abnormalities, Multiple, Alagille syndrome, Cardiovascular Abnormalities, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, bile duct disorder, biliary tract disorder, cardiovascular disorder, cholestasis, congenital heart disease, hereditary disease, intrahepatic cholestasis, liver disorder | Active, not recruiting | Phase 3 | 2026-10-02 | NCT05035030 | |
| Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment | Digestive System Diseases, Hepatic Insufficiency, Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, liver disorder, liver failure, neoplasm | Recruiting | Phase 1 | 2026-06-02 | NCT04617522 | |
| Radiprodil in Participants With Hepatic Impairment | Hepatic Impairment | Recruiting | Phase 1 | 2026-05-08 | NCT07457229 | |
| Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics | Ascites, Digestive System Diseases, Fibrosis, Fibrosis, Liver, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cirrhosis of liver, liver disorder | Recruiting | Phase 1 | 2025-09-05 | NCT05490888 | |
| Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis | Digestive System Diseases, fatty liver disease, liver disorder, metabolic dysfunction-associated steatohepatitis, metabolic dysfunction-associated steatotic liver disease | Active, not recruiting | Phase 2 | 2025-04-18 | NCT05979779 |